A Phase 3 interventional study of Bempedoic acid and Ezetimibe in Hypercholesterolemia, Atherosclerosis and Statin Adverse Reaction, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-11.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 7th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 10th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 7th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 3, and was the 10th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
Drug: Bempedoic acid · Drug: Ezetimibe
Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
Drug: Ezetimibe · Other: Placebo
bempedoic acid 180 mg tablet
Also known as: ETC-1002
ezetimibe 10 mg tablet
Also known as: Zetia
matching placebo tablet
Also known as: placebo control
Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Bempedoic Acid = BA. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Week 12
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[non-HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Week 12
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[TC value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Week 12
Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for apoB. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in apoB was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing apoB data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
Time frame: Week 12
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for hsCRP. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100.
Time frame: Week 12
Percent Change From Baseline to Week 12 in Triglycerides (TGs)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to D 1. Percent change from baseline was calculated as: \[(TGs value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 12
Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs, defined as an adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and prior to the last dose of double-blind study drug + 30 days, were collected and reported.
Time frame: Up to approximately 16 weeks
Percent Change From Baseline to Weeks 4 and 8 in LDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(LDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 4 and Week 8
Percent Change From Baseline to Weeks 4 and 8 in Non-HDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for Non-HDL-C. Baseline was defined as the mean of the Non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(Non-HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 4 and Week 8
Percent Change From Baseline to Weeks 4 and 8 in TC
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TC value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 4 and Week 8
Percent Change From Baseline to Weeks 4 and 8 in TGs
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TGs value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 4 and Week 8
Percent Change From Baseline to Weeks 4 and 8 in HDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
Time frame: Week 4 and Week 8
Absolute Change From Baseline to Weeks 4, 8, and 12 in LDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Absolute change from baseline was calculated as: LDL-C value at Week 4, 8, or 12 minus Baseline value.
Time frame: Week 4, Week 8 and Week 12
Out of the 269 participants who were randomized to the double-blind treatment period, 181 participants were randomized to bempedoic acid and 88 participants to placebo. One participant in the placebo group was randomized but never started treatment.
| Milestone | Placebo | Bempedoic Acid |
|---|---|---|
| Started | 88 | 181 |
| Completed | 81 | 176 |
| Not completed | 7 | 5 |
| Withdrew: Withdrawal by patient | 2 | 0 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Bempedoic Acid = BA. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) | 4.99 ± 2.299 | -23.46 ± 1.945 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[non-HDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | 5.19 ± 2.202 | -18.38 ± 1.668 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[TC value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | 2.88 ± 1.553 | -15.11 ± 1.282 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for apoB. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in apoB was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate. In the ANCOVA model, missing apoB data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB) | 4.74 ± 1.786 | -14.58 ± 1.497 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for hsCRP. Baseline was defined as the last non-missing value on or prior to Day 1. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | 2.088 (-32.143 to 49.224) | -32.521 (-55.556 to 10.714) |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to D 1. Percent change from baseline was calculated as: \[(TGs value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Triglycerides (TGs) | 9.23 ± 4.218 | 4.70 ± 3.068 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C) | -1.38 ± 1.389 | -7.27 ± 1.214 |
TEAEs, defined as an adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and prior to the last dose of double-blind study drug + 30 days, were collected and reported.
| Participants | Placebo | Bempedoic Acid |
|---|---|---|
| TEAEs | 39 | 88 |
| Non-serious TEAEs | 18 | 46 |
| Serious TEAEs | 3 | 5 |
| Deaths | 0 | 0 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(LDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Week 4 | 3.05 ± 1.442 | -28.04 ± 1.704 |
| Week 8 | 3.61 ± 1.773 | -25.51 ± 1.773 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for Non-HDL-C. Baseline was defined as the mean of the Non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(Non-HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Week 4 | 3.08 ± 1.362 | -22.17 ± 1.457 |
| Week 8 | 3.71 ± 1.660 | -20.04 ± 1.531 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TC value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Week 4 | 2.08 ± 1.000 | -18.33 ± 1.129 |
| Week 8 | 1.82 ± 1.110 | -16.63 ± 1.215 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for TGs. Baseline was defined as the mean of the TGs values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(TGs value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in TGs was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Week 4 | 6.00 ± 4.273 | 5.20 ± 2.536 |
| Week 8 | 7.68 ± 4.246 | 7.60 ± 2.849 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for HDL-C. Baseline was defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: \[(HDL-C value at Week 4 or 8 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment as a fixed effects and Baseline as a covariate.
| Percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Week 4 | 0.85 ± 1.204 | -7.73 ± 1.081 |
| Week 8 | -1.33 ± 1.272 | -7.75 ± 1.144 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analysed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Absolute change from baseline was calculated as: LDL-C value at Week 4, 8, or 12 minus Baseline value.
| milligrams per deciliter (mg/dL) | Placebo | Bempedoic Acid |
|---|---|---|
| Change from Baseline at Week 4 | 3.6 ± 15.65 | -37.4 ± 30.90 |
| Change from Baseline at Week 8 | 3.9 ± 19.22 | -34.5 ± 32.29 |
| Change from Baseline at Week 12 | 5.3 ± 23.96 | -32.9 ± 34.14 |
Collected over Up to approximately 16 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/87 (0%) | 3/87 (3.4%) | 18/87 (20.7%) |
| Bempedoic Acid | 0/181 (0%) | 5/181 (2.8%) | 46/181 (25.4%) |
| Event | Placebo | Bempedoic Acid |
|---|---|---|
| Pneumonia bacterialInfections and infestations | 1/87 | 0/181 |
| Poisoning deliberateInjury, poisoning and procedural complications | 1/87 | 0/181 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/87 | 0/181 |
| Subdural haemorrhageInjury, poisoning and procedural complications | 1/87 | 0/181 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/87 | 0/181 |
| Intestinal obstructionGastrointestinal disorders | 0/87 | 1/181 |
| BronchitisInfections and infestations | 0/87 | 1/181 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/87 | 1/181 |
| Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/87 | 1/181 |
| SyncopeNervous system disorders | 0/87 | 1/181 |
| Event | Placebo | Bempedoic Acid |
|---|---|---|
| Blood uric acid increaseInvestigations | 2/87 | 14/181 |
| Urinary tract infectionInfections and infestations | 5/87 | 5/181 |
| HeadacheNervous system disorders | 3/87 | 8/181 |
| Liver function test increasedInvestigations | 0/87 | 7/181 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/87 | 6/181 |
| NauseaGastrointestinal disorders | 0/87 | 5/181 |
| SinusitisInfections and infestations | 0/87 | 5/181 |
| VertigoEar and labyrinth disorders | 2/87 | 0/181 |
| Vulvovaginal mycotic infectionInfections and infestations | 2/87 | 0/181 |
| Diabetes mellitusMetabolism and nutrition disorders | 2/87 | 2/181 |
| Age, Continuous(years) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 63.7 ± 11.32 | 63.8 ± 10.77 | 63.8 ± 10.93 |
| Sex: Female, Male(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Female | 56 | 109 | 165 |
| Male | 32 | 72 | 104 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 43 | 66 |
| Not Hispanic or Latino | 65 | 138 | 203 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 10 | 11 | 21 |
| White | 75 | 165 | 240 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| LDL-C category(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| <130 mg/dL | 56 | 99 | 155 |
| ≥130 to <160 mg/dL | 24 | 53 | 77 |
| ≥160 mg/dL | 8 | 29 | 37 |
| Concomitant lipid-modifying therapy medications(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Statins | 25 | 59 | 84 |
| Fibrates | 3 | 7 | 10 |
| Nicotinic acid and derivatives | 4 | 3 | 7 |
| Bile acid sequestrants | 1 | 1 | 2 |
| Other lipid-modifying therapies | 8 | 19 | 27 |
| No concomitant lipid-modifying therapies | 47 | 92 | 139 |
| Concomitant illness: Cardiac disorder(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Participants with cardiac disorder | 22 | 49 | 71 |
| Participants without cardiac disorder | 66 | 132 | 198 |
| History of diabetes(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Participants with history of diabetes | 17 | 35 | 52 |
| Participants without history of diabetes | 71 | 146 | 217 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Jan 2018, 13 months.
Results were first posted in Apr 2020, 2 years 2 months after primary completion. A results delay was requested in Sep 2018.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid